These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26864210)

  • 1. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
    Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
    Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
    Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
    J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
    Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of oral ixabepilone in patients with advanced solid tumors.
    Deeken JF; Marshall JL; Pishvaian MJ; Hwang J; Ahlers CM; Clemens PL; Parker SM; Iacono L; LoRusso PM
    Cancer Chemother Pharmacol; 2014 May; 73(5):1071-8. PubMed ID: 24663504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.
    Plummer R; Woll P; Fyfe D; Boddy AV; Griffin M; Hewitt P; Carmichael J; Namouni F; Cohen M; Verrill M
    Clin Cancer Res; 2008 Dec; 14(24):8288-94. PubMed ID: 19088046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.
    Kunz PL; He AR; Colevas AD; Pishvaian MJ; Hwang JJ; Clemens PL; Messina M; Kaleta R; Abrahao F; Sikic BI; Marshall JL
    Invest New Drugs; 2012 Dec; 30(6):2364-70. PubMed ID: 22331549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixabepilone (Ixempra) for breast cancer.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I trial of dasatinib and ixabepilone in patients with solid tumors.
    Herbolsheimer P; Kapoor R; Smith KL; Perry D; Verma N; Veytsman I; Jelinek J; Swain SM
    Invest New Drugs; 2013 Feb; 31(1):92-8. PubMed ID: 22392508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
    Boku N; Muro K; Machida N; Hashigaki S; Kimura N; Suzuki M; Lechuga M; Miyata Y
    Invest New Drugs; 2014 Apr; 32(2):261-70. PubMed ID: 23665950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
    Egerton N
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Dubois SG; Shusterman S; Ingle AM; Ahern CH; Reid JM; Wu B; Baruchel S; Glade-Bender J; Ivy P; Grier HE; Adamson PC; Blaney SM
    Clin Cancer Res; 2011 Aug; 17(15):5113-22. PubMed ID: 21690570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
    Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
    Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
    Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
    Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.